Ligand Pharmaceuticals updates channels for material disclosures

Ligand Pharmaceuticals filed an update explaining that it has posted materials about its private placement investment in Athira Pharma, Inc. on its investor relations website and certain social media accounts.

Rhea-AI Filing Summary

Ligand Pharmaceuticals filed an update explaining that it has posted materials about its private placement investment in Athira Pharma, Inc. on its investor relations website and certain social media accounts. These posts provide more detail on the investment for interested readers.

The company also reiterates how it shares important information with the public. Ligand states that material updates may appear through SEC filings, its investor relations site, press releases, public conference calls, webcasts, its X (Twitter) account @Ligand_LGND and its LinkedIn page. Investors and other stakeholders are encouraged to review these channels regularly, and any changes to this list will be updated on the investor relations page.

8-K Event Classification

Item 7.01 — Regulation FD Disclosure

1 item

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Ligand Pharmaceuticals (LGND) disclose in this 8-K?

Ligand Pharmaceuticals disclosed that it posted materials regarding its private placement investment in Athira Pharma, Inc. on its investor relations page and certain social media accounts.

Where can investors find information about Ligand Pharmaceuticals' investment in Athira Pharma?

Investors can find information about the Athira Pharma investment on Ligand's investor relations page at https://www.ligand.com/ and on certain social media accounts referenced by the company.

Which communication channels does Ligand (LGND) use to share material information?

Ligand uses SEC filings, its investor relations website, press releases, public conference calls, webcasts, its X (Twitter) account @Ligand_LGND, and its LinkedIn page to share material information with the public.

Why is Ligand highlighting its disclosure channels in this filing?

Ligand notes that information disclosed through its website and social media channels could be deemed material and emphasizes these outlets to support broad, non-exclusionary distribution and compliance with Regulation FD.

Will Ligand update investors if its disclosure channels change?

Yes. Ligand states that any updates to its list of disclosure channels will be posted on the investor relations page on its website.

Does this 8-K describe new financial results for Ligand Pharmaceuticals?

No. This 8-K focuses on communication and disclosure practices and the posting of materials about a private placement investment, rather than on new financial results.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/18/2025 - 04:11 PM EST Learn about SEC filing dates

LIGAND PHARMACEUTICALS INC false 0000886163 0000886163 2025-12-18 2025-12-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 18, 2025

LIGAND PHARMACEUTICALS INCORPORATED

(Exact Name of Registrant as Specified in Its Charter)

Delaware		001-33093		77-0160744
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification No.)
555 Heritage Drive, Suite 200
Jupiter
Florida				33458
(Address of principal executive offices)				(Zip Code)

(858) 550-7500

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		LGND		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On December 18, 2025, Ligand Pharmaceuticals Incorporated (“Ligand”) posted materials regarding its private placement investment in Athira Pharma, Inc. on its investor relations page and certain of its social media accounts.

Ligand announces material information to the public through filings with the Securities and Exchange Commission, the investor relations page on Ligand’s website, available at https://www.ligand.com/, press releases, public conference calls, webcasts, Ligand’s X (Twitter) account (@Ligand_LGND) and Ligand’s LinkedIn page, in order to achieve broad, non-exclusionary distribution of information to the public and for complying with its disclosure obligations under Regulation FD.

The information disclosed by the foregoing channels could be deemed to be material information. As such, Ligand encourages investors, the media and others to follow the channels listed above and to review the information disclosed through such channels. Any updates to the list of disclosure channels through which Ligand announces information will be posted on the investor relations page on Ligand’s website.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				LIGAND PHARMACEUTICALS INCORPORATED
Date: December 18, 2025				By:		/s/ Andrew Reardon
				Name:		Andrew Reardon
				Title:		Chief Legal Officer and Secretary